Dr. Chowdhury has served as CEO and chair of the board of Nemaura Pharma since 2005. He is sole inventor on more than 50 granted and pending patents across over 15 technology platforms within the medical device and pharmaceutical sectors. He has authored Textbook Chapters on Nano-biosciences for Wiley and Elsevier, and serves on the Board of Medilink East Midlands, UK. Dr. Chowdhury holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and Doctorate from the University of Oxford on nano-medicine and drug delivery.
Kathryn received a Degree and Masters in Chemistry from the University of Oxford in 1998, and qualified as a Chartered Accountant in 2001. Ms. Farrar worked within the audit department at KPMG for 9 years, prior to joining Nemaura Pharma Limited in 2010, where she has served as the Accounts Manager. Her responsibilities included the preparation and management of the accounts of Nemaura Pharma and related companies.
Dr Wessling holds a Masters in Chemistry and Pharmacy, and a PhD (Dr.rer.nat.) from the University of Bonn. His early career in management (1981-87) with Beiersdorf AG and Altana AG subsequently led to his appointment as VP Business Development worldwide for LTS Lohmann Therapie-Systeme, the developer and manufactuer of innovative transdermal systems and oral films incorporating active substances. Dr Wessling built a successful commercial career with LTS, helping to grow the global pharmaceutical company to become the world’s largest Transdermal Patch Manufacturer, with 1,300 employees. He was appointed Senior VP Corporate Development in 2000, a position he held until 2016. During that period Dr Wessling was a Board Delegate LTS Lohmann Therapy-Systems Inc. N.J., USA (1994-2016), Managing Director CRS GmbH (2006-14) and Managing Director IIS GmbH (2011-16) – both subsidiaries of LTS.
He is a respected senior expert for the Bundesverband der Pharmazeutischen Industrie e.V. (BPI), the Federal Association of the Pharmaceutical Industry in Germany, and led the Innovation and R&D Committee between 2004 – 2010.
Steve is a pharmaceutical scientist by training and has over 30 years’ development experience within large and small organisations including over 20 years with Astra Zeneca. His experience spans a wide range of dosage form technologies including oral, inhalation and transdermal platforms. He has a strong background in Quality by Design led late stage development, holds Lean Sigma Black Belt, and has a proven track record in senior technical management.
David is a trained chemist with over 35 years’ experience in the Pharmaceutical Industry spanning deal brokering, marketing, strategic planning, finance, business development and acquisitions. He is a skilled negotiator who has closed a number of major deals for inward and outward licensing for pharmaceutical products, delivery systems and technologies. He has also provided licensing training for a number of multinational pharma companies and training organisations and has published widely, (he is the author of the best-selling report, “Scrip’s Practical Guide to Pharmaceutical Licensing”). David is also an accredited “Certified Licensing Professional”.
Jonathan was educated at the University of Oxford where he obtained his M.A. and D.Phil. in Chemistry. Subsequently the Faculty of Medicine awarded him a D.Sc. In May 2004 he joined The School of Pharmacy, University of London where he is professor of Biophysical chemistry. He has held academic posts at the Universities of London, Strathclyde, Nottingham, Cardiff and Greenwich. During his career he has been involved in the supervision of over 60 Ph.D. students. He holds visiting professorships at the North West University, Potchefstroom, South Africa and Monash University, Melbourne, Australia.
His major research interests are in the application of physical chemistry to drug delivery, with special reference to the skin. He has been elected to Fellowships of the Royal Society of Chemistry and the American Association of Pharmaceutical Scientists and was a founder member of Skin Forum. Over the years he has contributed to over 500 publications and serves on editorial boards of the major pharmaceutical science journals. He has given numerous plenary lectures in Europe, the US, Japan and Australasia. He consults for the industry on aspects of drug delivery particularly concentrating on dermal and transdermal delivery.
Professor Khan has over 35 years’ experience of drug discovery, pharmaceutical development, registration and managing pharmaceutical scientists. His experience includes 20 years as Head of Pharmaceutical Development for Boots Pharmaceuticals and Knoll and two years as Director for OSI where he managed their pharmaceutical development, analytical operations and DMPK. Professor Khan has also held various product development and management positions with Abbott Laboratories, and Beecham Pharmaceuticals. In these roles, he developed medicines for several therapeutic areas including antibiotics, anti-depressant, anti-inflammatory, anti-obesity, psychosis, cardiovascular, pain, cancer, Parkinson’s disease, diabetes and skin. Professor Khan developed and contributed to the launch of two once a day controlled release dosage forms. His expertise range from development for phase 1 to phase 3- 4 and significant experience of bringing prescription and OTC products to market on a global level (and has contributed to the registration and launch of over 60 pharmaceutical products). He is a Qualified person under the EC quality assurance directive.
Professor Khan has authored or co-authored more than 40 scientific publications and is an inventor of several development patents. He has been an invited speaker at many national and international conferences.